Introduction
Startle epilepsy (StEp) was first described in 1955. 1 It is mostly seen in patients with static or progressive encephalopathy in addition to comparatively fewer clinically normal cases. [2] [3] [4] [5] Among the etiological causes are perinatal anoxia, stroke, Sturge-Weber syndrome, porencephalic cyst, postinflammatuar changes, dysplastic lesions, Down syndrome and familial neonatal convulsions. The insult typically occurs within the first 2 years of life and is often preor perinatal. The onset of StEp is in childhood or early adolescence. StEp is a well-defined clinical condition related to above-mentioned early lesions of the motor cortex. Neuroimaging findings can be normal, or it may show localized or diffuse lesions. The lateralized lesions usually involve sensorimotor Seizure (2008) 
Summary
Purpose: To evaluate the efficacy and tolerability of Levetiracetam as an add-on therapy in patients with startle epilepsy (StEp). Methods: Ten (7 males and 3 females) were enrolled in the study. LEV was started at 500 mg bid, escalating over 1-2 weeks to maximal doses of 3000 mg daily, based on seizure control and tolerance for 13-28 months.
Results: The onset of startle seizures in patients with StEp varied from birth to 11 years. Six in 10 patients gave good responses to the treatment. There were adverse effects in three patients. Conclusion: Many AEDs have been used by medically intractable patients with StEp for many years but the results were almost discouraging. It was observed that 60% of the patients gave good response to LEV. Advanced studies are required to indicate the efficiency of LEV which proved to be effective on animals with audiogenic seizures on reflex epilepsies. # 2008 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved. and premotor cortex, and white matter. Focal or generalized atrophy is reported. 6 There are a few case reports or papers on groups of limited number of patients with StEp. The treatment of StEp is not always successful because total control of seizures is nearly impossible. The prognosis is usually bad especially in patients with preexisting severe encephalopathies. Because of the scarcity of patients with StEp, drug trials involving only a few patients could be done. 2, 3, 7 Levetiracetam (LEV) is well tolerated with favorable pharmacokinetic profile that includes minimal protein binding, lack of hepatic metabolism and twice a day dosing. [8] [9] [10] [11] [12] In this study our aim is to evaluate prospectively the efficacy and tolerability of LEV as an add-on therapy in patients with StEp.
Patients and methods
Out of 7759 patients, thirty with seizures triggered by unexpected stimulus have been diagnosed as StEp in Epilepsy Outpatient Clinic of Neurology Department since 1979. Only thirteen of 30 patients could be followed since only they came for their controls regularly while the others showed up either rarely or never for their follow-ups. The patients' files are reviewed with respect to their personal history, the onset of seizures (startle and spontaneous), frequency of seizures, provoking factors, neurological examination, mental retardation, neuroradiological findings, previously and currently used antiepileptic drugs (AEDs), responses of their spontaneous and startle seizures to LEV. Only 3 of 13 patients had good control seizure, i.e. they had no more startle seizures but only a few spontaneous seizures. They had no differences from the patients with intractable startle epilepsy in terms of the above-mentioned risk factors. The seizures of the other 10 patients were difficult to control despite the regular use of adequate AEDs. To test IQ, Alexander, Good enough and Cattell IQ tests are preferred to Wechsler Adult Intelligence Scale (WAIS) test since the latter has not been standardized for Turkish population. All patients were tested with only 1 of the three tests when applicable.
Their seizure diaries had been kept either by themselves or their families for 2 months before LEV treatment. They were included in the study to receive LEV treatment as an add-on therapy. LEV was started at 500 mg bid, escalating over 1-2 weeks to maximal doses of 3000 mg daily, based on seizure control and tolerance for 13-28 months. Patients had used upto 7 types of AEDs separately and during the study they used 1 to 3 types of AEDs simultaneously in addition to LEV. The dosage was adjusted individually for each patient with startle epilepsy. Visits were planned to be every 4 weeks, by alternating visits to hospital or calling the patient from home.
All patients and/or their parents gave written informed consent to the study which was done without both any specific funding and the involvement of any pharmaceutical company.
Results
There are 7 males and 3 females in our study group. The mean age of the patients is 26.93 AE 3.87 (21-34). In their previous history of the patients, birth hypoxia in 4, head trauma in 2, meningitis in 1, perinatal stroke in 1, prolonged birth and small gestational age in 1, subdural and intraventricular hematoma in 1, febrile or nonfebrile convulsion in 2 were found. Febrile and nonfebrile convulsions did not recur until the onset age of seizures. They had no previous histories of status epilepticus.
The onset of startle seizures in patients with StEp varied from birth to 11 years. The mean onset of age of epilepsy was 5.0 AE 4.71 years and the mean duration of epilepsy was 21.9 AE 5.82 years. The patients had two types of seizures, startle and spontaneous; both with the same characteristics: 7 patients had tonic seizures, 5 of whose were asymmetrical tonic. One patient had left focal motor seizures and 2 had partial and/or secondary generalized seizures in addition to their startle seizures. The main triggering stimuli for their startle seizures were sudden sound, found in all the patients, followed by touching or hitting any part of their bodies. The stimuli were sudden sounds in 10 patients, touching and sound in 7, stumbling in 2, fear, pain, excitement or scary dreams in 3 (Table 1) . Both startle and spontaneous seizures were seen in patients with StEp while spontaneous ones were rare.
Abnormality was found in 9 patients in their neurological examination, the most common findings being hemiparesis with hyperactive reflexes and an extensor plantar response in 50%.
Due to the diverse features of the patients, different IQ tests were performed for each. The mentally retarded and borderline IQ patients constituted 70% of the group.
4 of the patients were mentally retarded, (3 (30%) severe, 1 (10%) moderate) and 3 (30%) had borderline IQ. It was not required to measure the IQ of 2 patients who were clinically normal.
Magnetic resonance imaging (MRI) showed abnormality in 8 patients. The abnormal MRI findings in 5 of the patients varied from hyperintensities in periventricular region to bilateral periventricular gliosis with significant extension into cortical and subcortical deep white matter especially in the parietooccipital region, all of which can be defined as periventricular leukomalacia. Among the other MRI findings, there were left middle cerebral artery infarct in 1, hypoplasia in the left hemisphere, third ventricular dilatation and cystic lesion beginning from left frontal horn to occipital horn and skull defect due to operation in 1, and the other 2 patients displayed no abnormalities. EEG abnormalities were seen in all 10 patients. In the EEGs recorded during their follow-up, the most frequent findings were abnormal background activity in 9, epileptiform discharges in 3 and non-epileptiform discharges in 4.
The frequency of spontaneous seizures ranged from 1 to 15 a month before LEV and the frequency of their startle seizures varied from 20 to countless number of seizures per month before LEV in 10 patients with StEp. The average dose of LEV in patients was 1916.66 AE 861.20 (500-3000) mg. The average follow-up period was 22.66 AE 5.50 (12-28) months. Average numbers of monthly seizures as well as the distributions of AEDs used before and during LEV treatment are shown in Table 1 . Five of the patients had no spontaneous seizures also before LEV. The response rates in spontaneous seizures were 100% in 3 and no change in 2 after LEV. With respect to their startle seizures, 3 (30%) of the patients were seizure free, 3 (30%) had 50-90% seizure decrease, 1 (10%) had 25-50% seizure decrease, and 3 (30%) had seizure increase.
Six in 10 patients (60%) gave good responses to the treatment. In 3 patients, on the other hand, the frequency of seizures increased and in 1 the drug was somewhat ineffective on startle seizures. There were adverse effects in 3 patients. Although 50% decrease in the frequency of startle seizures was observed, LEV was discontinued in 1 of the mentally retarded patients (Case 8) due to agitation. The family of the other mentally retarded patient (Case 4) who felt dizziness stopped him from using the drug despite the decrease in the number of his seizures. The patient (Case 2) who complained from nervousness and forgetfulness was seizure free after many years. Therefore, she did not want to withdraw the drug. When the MRI findings are considered, no difference with respect to their responses to LEV is found between mild and severe abnormalities in terms of periventricular leukomalacia in 6 patients.
Mental retardation was not thought to be a worsening factor in terms of response to LEV.
Discussion
We were discouraged by our former experience of trying to take seizures under control in our patients with startle epilepsy especially when the high number of previously and currently used AEDs were considered along with the information in literature.
However, most of our cases with either periventricular leukomalacia or motor cortex lesions as well as mental retardation have potential risk for intractability of the treatment even without considering the fact that they have startle seizures.
The low number of patients in the series studies hindered the possibilities of controlled studies on startle epilepsy. In a study about the effectiveness of Clonazepam, the drug proved to have good seizure control for a certain period of time but the seizures recurred afterwards. 13 Another study about the effects of Clobazam showed that it obtained good control of seizures over a 22.75 months period. 2 Lamotrigine therapy was also shown to have good effects on patients with startle epilepsy. 7 LEV is a comparatively new AED which is rapidly and almost completely absorbed after oral administration. After 2 days of twice--daily dosing, steady state plasma levels are achieved. The elimination route of LEV is in the urine. LEV is <%10 protein bound and does not appear to interact with other drugs. These characteristics of LEV make it preferable among the other possible AEDs. The absence of drug interaction in LEV treatment is its other advantage for patients who use many AEDs. LEV is well tolerated, with adverse effects such as somnolance, asthenia, coordination difficulties or behavioral symptoms. [8] [9] [10] [11] [12] Our patients received LEV treatment for periods of 12-28 months. In 3 of our patients (30%) adverse effects were observed and 1 of them discontinued the drug because of agitation.
It was observed that 60% of the patients gave good response to the treatment. These patients maintained their good seizure control over the following months. It is difficult to predict whether the positive effects of LEV on seizure control will be preserved in the following years. However, it is a well-known fact that the effectiveness of AEDs decreases in time in patients with intractable epilepsy.
One important factor to consider in our patients was their being either mentally retarded or having borderline IQs. Therefore low good response rates could be expected from our patients, but no difference in terms of seizure control between them and the clinically normal patients was observed. There are two studies conducted on mentally retarded patients with epilepsy, which also convey no difference with respect to their becoming seizure free: 38-40% of the patients in both groups were seizure free. 14, 15 However, another study elucidated that mentally retarded patients and/or patients with behavioral problems showed more adverse effects. 16 LEV anticonvulsant activity was discovered in audiogenic seizure. LEV inhibited audiogenicinduced tonic and clonic convulsions in audiogenic seizure sensitive mice 17 and rats. 18 Although the pathophysiological mechanism of audiogenic seizures is different from startle epilepsy, they are important for being reflex seizures responsive to LEV.
Investigating reflex seizures further with human and animal experiences is important to illuminate the effect mechanisms of LEV, that is not well known yet.
